SCHEMBL1677080

SCHEMBL1677080

CCCCOB(OCC(C)C)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PCSK9 Q8NBP7 1/20 0.42
LTA4H P09960 2/20 0.39
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
ALDH1A1 P00352 4/20 0.34
TSHR P16473 3/20 0.34
TDP1 Q9NUW8 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
ALOX5 P09917 1/20 0.33
PPARG P37231 1/20 0.33
PPARA Q07869 1/20 0.33
MLNR O43193 1/20 0.33
NR1I2 O75469 1/20 0.33
ESR1 P03372 1/20 0.33
NR3C1 P04150 1/20 0.33
PGR P06401 1/20 0.33
ADRB2 P07550 1/20 0.33
CHRM2 P08172 1/20 0.33
ADRB1 P08588 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3289446 0.88 PCSK9 (0.52) PCSK9LTA4HCYP1A2CYP2C9CYP2C19
SCHEMBL3848571 0.86 ALDH1A1 (0.38) PCSK9CYP1A2ALDH1A1TSHRTDP1
SCHEMBL30545064 0.81 PCSK9 (0.48) PCSK9LTA4HALDH1A1TSHRMLNR
SCHEMBL30545060 0.81 PCSK9 (0.48) PCSK9LTA4HALDH1A1TSHRMLNR
SCHEMBL11711998 0.81 PCSK9 (0.48) PCSK9LTA4HALDH1A1TSHRMLNR
SCHEMBL14983388 0.78 LTA4H (0.42) PCSK9LTA4HCYP1A2CYP2C9CYP2C19
SCHEMBL7796509 0.77 MEN1 (0.42) PCSK9LTA4HCYP1A2ALDH1A1TSHR
SCHEMBL14983385 0.74 MGLL (0.44) PCSK9LTA4HCYP1A2CYP2C9CYP2C19
SCHEMBL14983499 0.74 CA1 (0.45) PCSK9LTA4HALDH1A1L3MBTL1NR1I2
SCHEMBL7799309 0.73 TSHR (0.59) PCSK9LTA4HCYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use TRANSTECH PHARMA, INC. (US) 2011-04-21 US disclosed
EP-1730118-A1 SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE Transtech Pharma, Inc. (US) 2006-12-13 EP disclosed
WO-2005080346-A1 SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE TRANSTECH PHARMA, INC. (US) 2005-09-01 WO disclosed
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use TRANSTECH PHARMA, INC. 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use PTPRO, PTPN5, PTPRE PCSK9 1245/4885LTA4H 1580/4885CYP1A2 222/4885
US-20050187277-A1 Substituted azole derivatives, compositions, and methods of use PTPRO, PTPN5, PTPRE PCSK9 1245/4885LTA4H 1580/4885CYP1A2 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.